Turn Therapeutics Announces Positive In-Vivo Data for Non-Melanoma Skin Cancer Candidate

LOS ANGELES, July 12, 2022 /PRNewswire/ -- Turn Therapeutics, a biotechnology company developing innovative products for infectious disease, advanced wound care, and dermatology, today announced positive in-vivo data for its therapeutic candidate (GX-03) as a non-invasive treatment for...

Click to view original post